Angiotensin II reduces cardiac AdipoR1 expression through AT1 receptor/ROS/ERK1/2/c-Myc pathway

PLoS One. 2013;8(1):e49915. doi: 10.1371/journal.pone.0049915. Epub 2013 Jan 22.

Abstract

Adiponectin, an abundant adipose tissue-derived protein, exerts protective effect against cardiovascular disease. Adiponectin receptors (AdipoR1 and AdipoR2) mediate the beneficial effects of adiponectin on the cardiovascular system. However, the alteration of AdipoRs in cardiac remodeling is not fully elucidated. Here, we investigated the effect of angiotensin II (AngII) on cardiac AdipoRs expression and explored the possible molecular mechanism. AngII infusion into rats induced cardiac hypertrophy, reduced AdipoR1 but not AdipoR2 expression, and attenuated the phosphorylations of adenosine monophosphate-activated protein kinase and acetyl coenzyme A carboxylase, and those effects were all reversed by losartan, an AngII type 1 (AT1) receptor blocker. AngII reduced expression of AdipoR1 mRNA and protein in cultured neonatal rat cardiomyocytes, which was abolished by losartan, but not by PD123319, an AT2 receptor antagonist. The antioxidants including reactive oxygen species (ROS) scavenger NAC, NADPH oxidase inhibitor apocynin, Nox2 inhibitor peptide gp91 ds-tat, and mitochondrial electron transport chain complex I inhibitor rotenone attenuated AngII-induced production of ROS and phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. AngII-reduced AdipoR1 expression was reversed by pretreatment with NAC, apocynin, gp91 ds-tat, rotenone, and an ERK1/2 inhibitor PD98059. Chromatin immunoprecipitation assay demonstrated that AngII provoked the recruitment of c-Myc onto the promoter region of AdipoR1, which was attenuated by PD98059. Moreover, AngII-induced DNA binding activity of c-Myc was inhibited by losartan, NAC, apocynin, gp91 ds-tat, rotenone, and PD98059. c-Myc small interfering RNA abolished the inhibitory effect of AngII on AdipoR1 expression. Our results suggest that AngII inhibits cardiac AdipoR1 expression in vivo and in vitro and AT1 receptor/ROS/ERK1/2/c-Myc pathway is required for the downregulation of AdipoR1 induced by AngII.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetyl-CoA Carboxylase / metabolism
  • Adenylate Kinase / metabolism
  • Adiponectin / blood
  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Angiotensin II / pharmacology*
  • Animals
  • Animals, Newborn
  • Blood Vessels / drug effects
  • Blood Vessels / metabolism
  • Cardiomegaly / genetics
  • Cardiomegaly / metabolism
  • Cardiomegaly / pathology
  • Enzyme Activation / drug effects
  • Gene Expression Regulation / drug effects*
  • MAP Kinase Signaling System / drug effects*
  • Male
  • Membrane Glycoproteins / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / metabolism
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism*
  • Myocytes, Cardiac / pathology
  • NADPH Oxidase 2
  • NADPH Oxidases / antagonists & inhibitors
  • Phosphorylation / drug effects
  • Proto-Oncogene Proteins c-myc / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptors, Adiponectin / genetics*
  • Receptors, Adiponectin / metabolism*

Substances

  • Adiponectin
  • Membrane Glycoproteins
  • Proto-Oncogene Proteins c-myc
  • Reactive Oxygen Species
  • Receptor, Angiotensin, Type 1
  • Receptors, Adiponectin
  • adiponectin receptor 1, rat
  • Angiotensin II
  • Cybb protein, rat
  • NADPH Oxidase 2
  • NADPH Oxidases
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Adenylate Kinase
  • Acetyl-CoA Carboxylase

Grants and funding

This work was supported by grants from the National Nature Science Foundation of China (Nos. 30871014 and 30973316) and the National Basic Research Program of China (973 Program 2007CB512004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.